Your State:
Bookmark the new Broker Launchpad – guiding you to the right tool at the right time.
With 5 being the highest, how would you rate your experience on a scale of 1-5?
Jan 31, 2022
We now cover the oral antiviral drugs Paxlovid and Lagevrio at no additional cost to members as part of their pharmacy benefits. Both drugs received emergency use authorization from the U.S. Food and Drug Administration (FDA) late last year. They are only available by prescription and can reduce the chance of hospitalization and potential for severe illness when taken within five days after symptoms appear.
During the Coronavirus Public Health Emergency, the federal government will pay the ingredient drug costs of FDA-authorized COVID-19 oral antivirals. Employers will not have to pay the ingredient drug costs and members will have no cost share for these drugs. Claims for COVID-19 oral antivirals will be excluded from rebate calculations and other client pricing guarantees for ASO clients.
This coverage will continue for the length of the public health emergency and is retroactive to the date of FDA authorization.
Coverage limitations:
Please contact your sales representative for more information.
The Medicaid Renewal Broker Resource page on Broker Hub reflects a brand-new design that makes it easier for you to find the resources you need, right now, as you continue to help disenrolled individuals stay covered. Because Medicaid disenrollments have been underway for over a year, we’ve shif...
Some Large Group medical clients with embedded vision coverage are unable to find Blue View Vision providers using the Find Care search tool on anthem.com and in the Sydney℠ Health mobile app. For them, the system is only displaying medical plan providers. Affected members can use the Guest Sear...